David Hallal is a 30-year veteran in the biopharmaceutical industry with expertise in early-stage company building as well as operating large multinational biotech companies. He also is Chairman of AlloVir, an ElevateBio portfolio company.

Dr. Mitchell Finer serves as President of Research and Development of ElevateBio as well as CEO of Life Edit Therapeutics, an ElevateBio company developing a next-generation gene editing platform. He is a co-founder of ElevateBio and serves on its Board of Directors. Dr. Finer also serves as an executive partner at MPM Capital.

Vikas Sinha brings more than 25 years of experience in executive finance roles in the life sciences industry. He is CFO and co-founder of ElevateBio and also serves as President and CFO of AlloVir, an ElevateBio portfolio company.

Jacob Abrams joined ElevateBio in 2020, and as general counsel, he leads the company’s legal function.

Bhakti has over 15 years of experience in biotech, consulting, and financial services including corporate finance, business development, strategy, and business process re-engineering.

For over 25 years, Melissa has worked on the development of cell therapies using human adult and pluripotent stem cells in academia and industry. Her work involves discovery research and the translation of this research into therapeutic products, including developing strategies for cell manufacturing, preclinical development, and paving the regulatory path for the development of stem cell therapies. Melissa serves as a member of the Board of Directors of TreeFrog Therapeutics (developing iPS-derived cell therapies) and the International Society for Stem Cell Research (ISSCR). In addition, she serves on the scientific advisory committee of the Novo Nordisk Foundation Center for Stem Cell Medicine (ReNew).

Tedd leads the scientific development of the Life Edit Therapeutics gene-editing platform. He has more than 20 years of biotech experience focused on gene expression and pharmaceutical discovery and was previously Chief Scientific Officer at LifeEDIT Inc. when the company was a subsidiary of AgBiome.

Catherine Hu joined ElevateBio in 2021 to lead the company’s investor relations and corporate affairs functions. Prior to ElevateBio, Catherine led investor relations, corporate affairs, and patient advocacy functions at Scholar Rock, Inc. and was part of the investor relations team at Alexion Pharmaceuticals.

Missy has more than 15 years of experience in operations and people strategies. As a strategic thought partner to the leadership team, she identifies areas for operational improvement, provides insight and analysis on company strategy and operations, and ensures a continued focus on top priorities across the company.

Amit brings more than 20 years of experience to his role as Chief Information Officer. His IT strategy consists of four key pillars: (1) to drive manufacturing intelligence using Industry 4.0 concepts, digital twin, and enterprise-IT solutions; (2) to establish foundational artificial intelligence (AI) computing environment and data engines leading to enhanced drug discovery capabilities in various R&D areas; (3) to secure the environment with robust Cybersecurity and enterprise architecture programs, and (4) to create a cloud-based core IT infrastructure and a diverse end-user computing team.

Jill brings more than 20 years of scientific expertise and a broad background in immuno-oncology and cell-based therapeutics for cancer, as well as synthetic biology and process development for cell therapy. Jill leads the Cellular Engineering, Immunotherapy and Early Clinical Development functions at ElevateBio.

Clare leads corporate development and operations at Life Edit Therapeutics. She has more than 20 years of pharmaceutical industry experience focused on drug discovery and business development and previously ran business development at LifeEDIT Inc., when the company was a subsidiary of AgBiome.